CLINICAL_TRIALS
trial_result
· 2026-03-17
Clinical Trial Update: A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes [Phase 3]
Summary
Phase 3 trial evaluating 0.003% AR-15512 for dry eye disease completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alcon Research | Conditions: Dry Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-03-17